...
首页> 外文期刊>Investigational New Drugs >Antitumor efficacy and apoptotic activity of substituted chloroalkyl 1H-benz[de]isoquinoline-1,3-diones: a new class of potential antineoplastic agents
【24h】

Antitumor efficacy and apoptotic activity of substituted chloroalkyl 1H-benz[de]isoquinoline-1,3-diones: a new class of potential antineoplastic agents

机译:取代氯烷基1H-苯并[de]异喹啉-1,3-二酮的抗肿瘤功效和凋亡活性:一类新的潜在抗肿瘤药

获取原文
获取原文并翻译 | 示例

摘要

A series of ten chloroalkyl 1H-benz[de]isoquinoline-1,3-diones (naphthalimides) were synthesized and evaluated for antitumor activity. Amongst them, new compounds 2d and 2i carrying a 6-NO2 substituent in the aromatic portion of the molecule possessed significant antineoplastic activity. The most active compound 2i had elicited significant cytotoxicity in 15 human tumor cell lines namely Leukemia: MOLT-4, HL-60; Lymphoma: U-937; Colon: 502713, HT-29, SW-620, HCT-15, COLO-205; Liver: Hep-2; Prostate DU-145, PC-3; Breast: MCF-7; Neuroblastoma: IMR-32, SK-N-SH and Ovary: OVCAR-5 out of the 17 cell lines screened. Flow cytometric analysis performed to study the effect of compound 2i on the progression of cell cycle of MOLT-4 cells, revealed rise in sub-G1 fraction and concomitant accumulation of cells in S and G2/M phases, indicating apoptosis, mitotic arrest and/or delay in exit of daughter cells from mitotic cycle respectively. It also induced caspase-mediated apoptosis of MOLT-4 cells in a dose dependant manner. Light and electron microscopic studies revealed characteristic morphology of apoptotic MOLT-4 cells after in vitro treatment with 10 μM concentration of the compound. Apoptosis induction was also observed in HL-60 cells by compounds 2d and 2i to an extent much greater than camptothecin and cis-platin at 10 μM concentration. Both the compounds have shown minimal suppressive effect on human PBMC having high IC50 values of 3,582 and 1,536 μM respectively. These compounds inhibited DNA and RNA synthesis in murine ascites Sarcoma-180 tumor cells in vitro at 8 μM concentration. Above results indicate promising chemotherapeutic potential of the key compound 2i.
机译:合成了一系列十个氯烷基1H-苯并[de]异喹啉-1,3-二酮(萘二甲酰亚胺),并评估了其抗肿瘤活性。其中,在分子的芳族部分带有6-NO2 取代基的新化合物2d和2i具有显着的抗肿瘤活性。活性最高的化合物2i已在15种人类肿瘤细胞系(白血病:MOLT-4,HL-60; 15)中产生了明显的细胞毒性。淋巴瘤:U-937;结肠:502713,HT-29,SW-620,HCT-15,COLO-205;肝:Hep-2;前列腺DU-145,PC-3;乳房:MCF-7;神经母细胞瘤:IMR-32,SK-N-SH和卵巢:筛查的17种细胞系中的OVCAR-5。进行流式细胞术分析以研究化合物2i对MOLT-4细胞的细胞周期进程的影响,揭示亚G1 分数的升高以及S和G2 / M期细胞的伴随积累分别表示凋亡,有丝分裂停滞和/或子细胞退出有丝分裂周期的延迟。它还以剂量依赖性方式诱导胱天蛋白酶介导的MOLT-4细胞凋亡。光和电子显微镜研究揭示了在体外用10μM浓度的化合物处理后凋亡的MOLT-4细胞的特征形态。化合物2d和2i在HL-60细胞中也观察到凋亡诱导,其程度比喜树碱和顺铂在10μM浓度下大得多。两种化合物对人PBMC的抑制作用最小,分别具有3,582和1,536μM的高IC50值。这些化合物在体外以8μM的浓度抑制鼠腹水肉瘤180肿瘤细胞中的DNA和RNA合成。以上结果表明关键化合物2i具有良好的化学治疗潜力。

著录项

  • 来源
    《Investigational New Drugs》 |2011年第3期|p.434-442|共9页
  • 作者单位

    Department of Anticancer Drug Development, Chittaranjan National Cancer Institute, Kolkata, 700026, India;

    Department of Anticancer Drug Development, Chittaranjan National Cancer Institute, Kolkata, 700026, India;

    Department of Anticancer Drug Development, Chittaranjan National Cancer Institute, Kolkata, 700026, India;

    Pharmacology Division, Indian Institute of Integrative Medicine, Canal Road, Jammu-Tawi, 180001, India;

    Pharmacology Division, Indian Institute of Integrative Medicine, Canal Road, Jammu-Tawi, 180001, India;

    Pharmacology Division, Indian Institute of Integrative Medicine, Canal Road, Jammu-Tawi, 180001, India;

    Pharmacology Division, Indian Institute of Integrative Medicine, Canal Road, Jammu-Tawi, 180001, India;

    Pharmacology Division, Indian Institute of Integrative Medicine, Canal Road, Jammu-Tawi, 180001, India;

    Pharmacology Division, Indian Institute of Integrative Medicine;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Novel antitumor agents; Human tumor cell lines; Cytotoxicity assay; Cell cycle; Apoptosis;

    机译:新型抗肿瘤药物;人肿瘤细胞系;细胞毒性测定;细胞周期;凋亡;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号